CANbridge Reaches Full Enrollment in Phase 2 Trial for Gaucher Disease in China

17 October 2023 | Tuesday | News

CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease (GD) Types I and III, has reached full enrollment
Image Source : Public Domain

Image Source : Public Domain

Phase 2 is a randomized, double-blind, dose comparison study to evaluate the efficacy, safety and pharmacokinetics of CAN103 in newly treated GD patients, with extension period. This trial will serve as a potential registrational trial for CAN103.

CAN103 is the first clinical stage enzyme replacement therapy (ERT) being developed for GD in China.  According to Frost & Sullivan, there were approximately 3,000 GD patients in China in 2020. Due to reimbursement barriers, most patients with GD in China currently lack access to approved ERT treatments. CAN103 is an ERT under development by CANbridge, as part of its rare disease collaboration with WuXi Biologics (2269.HK), for the long-term treatment of adults and children with GD Types I and III.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in